secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001437749-26-010634
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed
--------------------------------------------------------------------------------

- Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).
- Closed zaltenibart deal with Novo Nordisk Nov 2025, receiving $240M upfront; repaid $67.1M term loan and $17.1M convertible notes.
- FDA approved YARTEMLEA (narsoplimab) for TA-TMA Dec 2025; commercial launch began Jan 2026.
- Q4 OMIDRIA royalties $9.2M on $30.7M net sales vs. $10.1M on $33.6M in prior year.
- Operating expenses fell to $122.8M in FY25 from $167.0M in FY24, down $44.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/0001437749-26-010634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/omer20251116_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer